scholarly journals A New Type Influenza (Pandemic H1N1 2009)-Its Onset and Progress till Now-

2010 ◽  
Vol 14 (1) ◽  
pp. 1-3
Author(s):  
Nobuhiko OKABE
2011 ◽  
Vol 25 (1) ◽  
pp. 23-28 ◽  
Author(s):  
Amparo Larrauri ◽  
Camelia Savulescu ◽  
Silvia Jiménez-Jorge ◽  
Pilar Pérez-Breña ◽  
Francisco Pozo ◽  
...  

2011 ◽  
Vol 140 (5) ◽  
pp. 814-817 ◽  
Author(s):  
Y. H. LEUNG ◽  
W. L. LIM ◽  
M. H. WONG ◽  
S. K. CHUANG

SUMMARYDuring the early phase of the influenza pandemic in 2009, all cases of laboratory-confirmed pandemic (H1N1) 2009 (pH1N1) infection required compulsory isolation in hospital. These cases were offered oseltamivir treatment and only allowed to be discharged from the hospital when three consecutive respiratory specimens were negative for the virus by reverse transcription–polymerase chain reaction (RT–PCR). We reviewed the case records of these patients to assess the viral shedding kinetics of the pH1N1 virus. We defined viral shedding duration as the interval from illness onset date to the date of collection of the last positive specimen from the patients. Fifty-six patients were included in the study, of whom 96% received oseltamivir. The median viral shedding duration of pH1N1 virus by viral culture and RT–PCR were 3 days and 4 days, respectively. Patients who started oseltamivir treatment >48 h after onset had a significantly longer median viral shedding duration by viral culture than those who started treatment within 48 h of onset (4 days vs. 2 days, P=0·014).


2011 ◽  
Vol 5 (09) ◽  
pp. 658-663 ◽  
Author(s):  
Vítor Duque ◽  
João Vaz ◽  
Vanda Mota ◽  
Célia Morais ◽  
Saraiva Da Cunha ◽  
...  

Introduction: In June 2009, the World Health Organization declared an influenza pandemic associated with the pandemic (H1N1) 2009 strain. It was summer in the northern hemisphere, and therefore travelling and vacation time, which also provided an increased opportunity for the dissemination of respiratory diseases. Methodology: We reviewed the paper case report forms from all the patients with influenza-like illnesses with nasopharyngeal samples submitted for laboratory diagnosis of pandemic (H1N1) 2009 infection during the first wave of pandemic influenza that occurred between June and August 2009, in the central region of Portugal. Results: From all the patients with influenza-like illnesses, one third was found positive for pandemic (H1N1) 2009. Individuals under the age of 29 (75%) were the most affected. Most of the patients (91%) presented with fever. A group of symptoms were positively correlated with the probability of pandemic (H1N1) 2009 infection: cough, epistaxis, lack of dyspnea or vomiting, fever, headache and myalgia. Conclusions: During the first wave of the pandemic influenza, young individuals were the most affected, and in the ambulatory setting, presentation was of a mild febrile illness without complications.


2010 ◽  
Vol 84 (15) ◽  
pp. 7662-7667 ◽  
Author(s):  
Adrianus C. M. Boon ◽  
Jennifer deBeauchamp ◽  
Scott Krauss ◽  
Adam Rubrum ◽  
Ashley D. Webb ◽  
...  

ABSTRACT Our ability to rapidly respond to an emerging influenza pandemic is hampered somewhat by the lack of a susceptible small-animal model. To develop a more sensitive model, we pathotyped 18 low-pathogenic non-mouse-adapted influenza A viruses of human and avian origin in DBA/2 and C57BL/6 mice. The majority of the isolates (13/18) induced severe morbidity and mortality in DBA/2 mice upon intranasal challenge with 1 million infectious doses. Also, at a 100-fold-lower dose, more than 50% of the viruses induced severe weight loss, and mice succumbed to the infection. In contrast, only two virus strains were pathogenic for C57BL/6 mice upon high-dose inoculation. Therefore, DBA/2 mice are a suitable model to validate influenza A virus vaccines and antiviral therapies without the need for extensive viral adaptation. Correspondingly, we used the DBA/2 model to assess the level of protection afforded by preexisting pandemic H1N1 2009 virus (H1N1pdm) cross-reactive human antibodies detected by a hemagglutination inhibition assay. Passive transfer of these antibodies prior to infection protected mice from H1N1pdm-induced pathogenicity, demonstrating the effectiveness of these cross-reactive neutralizing antibodies in vivo.


Uirusu ◽  
2009 ◽  
Vol 59 (2) ◽  
pp. 139-144 ◽  
Author(s):  
Hitoshi OSHITANI

2010 ◽  
Vol 16 (8) ◽  
pp. 1265-1272 ◽  
Author(s):  
Chung-Chen Li ◽  
Lin Wang ◽  
Hock-Liew Eng ◽  
Huey-Ling You ◽  
Ling-Sai Chang ◽  
...  

Transfusion ◽  
2011 ◽  
Vol 51 (9) ◽  
pp. 1949-1956 ◽  
Author(s):  
Rieko Sobata ◽  
Chieko Matsumoto ◽  
Masashi Igarashi ◽  
Shigeharu Uchida ◽  
Shunya Momose ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document